GSA Capital Partners’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-94,917
| Closed | -$209K | – | 1770 |
|
|
2024
Q4 | $209K | Buy |
+94,917
| New | +$209K | 0.02% | 1394 |
|
|
2024
Q3 | – | Sell |
-813,399
| Closed | -$1.81M | – | 1713 |
|
|
2024
Q2 | $1.81M | Buy |
813,399
+364,270
| +81% | +$809K | 0.13% | 185 |
|
|
2024
Q1 | $1.2M | Sell |
449,129
-679,020
| -60% | -$1.82M | 0.1% | 325 |
|
|
2023
Q4 | $3.37M | Buy |
1,128,149
+11,494
| +1% | +$34.4K | 0.28% | 21 |
|
|
2023
Q3 | $1.09M | Buy |
1,116,655
+685,733
| +159% | +$672K | 0.09% | 351 |
|
|
2023
Q2 | $599K | Buy |
430,922
+318,338
| +283% | +$443K | 0.06% | 630 |
|
|
2023
Q1 | $179K | Buy |
112,584
+94,367
| +518% | +$150K | 0.02% | 1277 |
|
|
2022
Q4 | $113K | Buy |
+18,217
| New | +$113K | 0.01% | 1289 |
|
|
2021
Q4 | – | Sell |
-23,628
| Closed | -$285K | – | 1509 |
|
|
2021
Q3 | $285K | Buy |
+23,628
| New | +$285K | 0.03% | 1057 |
|
|
2021
Q1 | – | Sell |
-20,093
| Closed | -$522K | – | 1211 |
|
|
2020
Q4 | $522K | Buy |
20,093
+7,043
| +54% | +$183K | 0.09% | 407 |
|
|
2020
Q3 | $485K | Buy |
+13,050
| New | +$485K | 0.08% | 408 |
|
|
2019
Q3 | – | Sell |
-15,197
| Closed | -$707K | – | 1476 |
|
|
2019
Q2 | $707K | Buy |
+15,197
| New | +$707K | 0.08% | 449 |
|
|
2017
Q4 | – | Sell |
-9,050
| Closed | -$454K | – | 1624 |
|
|
2017
Q3 | $454K | Sell |
9,050
-655
| -7% | -$32.9K | 0.03% | 1023 |
|
|
2017
Q2 | $449K | Sell |
9,705
-26,623
| -73% | -$1.23M | 0.03% | 1060 |
|
|
2017
Q1 | $1.28M | Buy |
+36,328
| New | +$1.28M | 0.07% | 499 |
|
|
2015
Q4 | – | Sell |
-31,898
| Closed | -$752K | – | 1854 |
|
|
2015
Q3 | $752K | Buy |
31,898
+23,198
| +267% | +$547K | 0.04% | 860 |
|
|
2015
Q2 | $711K | Buy |
+8,700
| New | +$711K | 0.03% | 1133 |
|